3Davis T A,Grillo Lopez A J,Wite C A, et al.Rituximab anti- CD20 monoclonal antibody therapy in non-hodgkins lymphoma: safety and efficacy of retr-eatment[J].J Clin Oncol,2000, 18(17):3135.
3[1] Anderson Kc,Bates Mp,Slaughenhoupt BL,et al.Expression of human B cell-associated antigens on leukemias and lmphomas:a model of human B cell differention[J].Blood,1984,63:1424-1433.
4[2] Demidem A,Lam T,Alas S,et al.Chimeric anti-CD20(IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J].Cancer Biother Radiopharm,1997,12:177-186.
5[3] Taji H,Kagami Y,Okada Y,et al.Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody[J].Jpn J Cancer Res,1998,89:748-756.
6[4] Maloney DG.Preclinical and phase 1 and 2 trials of rituximab[J].Semin Oncol,1999,26:74-78.
7[5] Davis T,Levy R,White CA,et al.Rituximab:phase 2(P2) retretment(ReRx) study in patients(pts) with low-grade or follicular(LG/F) NHL[abstract][J].Blood,1998,92:414.
8[6] Davis T,Levy R,White CA,et al.Retretments with RITUXAN(rituximab,Idec-C2B8) have significant efficacy,do not cause harm,and are a viable minimally toxic altern-ative in relapsed or refractory nom-Hodgkins lymphoma(NHL)[abstract][J].Blood,1997,90:509.
